GET DAILY SIGNALSWhy Is Immunocore Holdings (IMCR) Stock Up +4.58% Today?
Key Takeaways
- +4.58% move: Shares of IMCR rose roughly 4.6% to about $29.70, up from a prior close of $28.40.
- Primary catalyst: A third-quarter earnings release and business update that highlighted significant clinical pipeline progress, including completed enrollment in the pivotal TEBE-AM melanoma trial.
- Secondary drivers: Underlying KIMMTRAK revenue growth of approximately 10% and a strong cash position of $901.3 million reinforced investor confidence.
- Earnings nuance: The company posted a wider quarterly net loss than expected, yet traders looked past the miss to focus on long-term pipeline catalysts.
- What to watch next: Topline overall survival data from TEBE-AM, additional brenetafusp data, and initiation of the DUET-UVEAL trial.
- For deeper insight into this ticker, explore Price Targets, Earnings, and Forecast pages.
- Discover AI-driven trading strategies across thousands of tickers by visiting Trending AI Robots.
Opening Summary
Immunocore Holdings plc (IMCR) is a commercial-stage biotechnology company headquartered in Oxfordshire, England, best known for KIMMTRAK (tebentafusp-tebn), its approved treatment for metastatic uveal melanoma, and a proprietary T-cell receptor (TCR) platform spanning oncology, infectious disease, and autoimmune indications. On Friday, November 6, 2026, the stock rallied roughly 4.58% to approximately $29.70, compared with a prior closing price of $28.40. The advance followed the company's third-quarter financial results and business update, which, despite a wider-than-anticipated quarterly loss, underscored meaningful progress across its late-stage clinical pipeline.
Earnings Results and Pipeline Update
The move was primarily an earnings-driven event. Immunocore reported third-quarter net product revenue of $102.2 million, a slight decline from $103.7 million a year earlier. Management attributed the dip to U.S. wholesaler stocking in the second quarter and one additional week of U.S. sales in the prior-year period, noting that underlying revenue growth was approximately 10% when adjusting for those factors. Nine-month KIMMTRAK net sales totaled $324.8 million, up 10% from $295.5 million a year ago. The company ended the quarter with $901.3 million in cash, cash equivalents, and marketable securities.
Even though the company posted a net loss of $14.2 million, or $0.28 per share—wider than consensus estimates—investors chose to focus on the pipeline. The pivotal Phase 3 TEBE-AM trial in previously treated advanced cutaneous melanoma completed enrollment of 540 patients, with topline overall survival data expected in the second quarter of 2027. This represents a major potential label-expansion opportunity for the company's lead immunotherapy franchise.
Promising Combination Data and New Trial Plans
Adding to the positive sentiment, Immunocore disclosed updated Phase 1 data from a combination of KIMMTRAK and brenetafusp in metastatic uveal melanoma. Among 17 evaluable first-line patients, the combination showed an overall response rate of 29% and a two-year overall survival rate of 70%. Based on these results, the company plans to initiate DUET-UVEAL, a randomized Phase 2/3 trial evaluating the combination in HLA-A*02:01-positive patients. Markets read the data as evidence that the company's dual T-cell engager approach could deepen its footprint in its core franchise.
Broader Pipeline Momentum
Beyond melanoma, the update highlighted diversification across the platform. Immunocore confirmed that the first person with type 1 diabetes has been dosed in a Phase 1 trial of IMC-S118AI, its first tissue-specific autoimmune candidate, marking an expansion into a large, high-need chronic disease category. The company also plans to file a clinical trial application for its second autoimmune program, IMC-U120AI, before year-end. In infectious disease, enrollment continued in the HIV candidate program, with additional data expected early next year. This breadth of catalysts helped underpin the stock's advance.
Market Context and Trading Activity
The rally unfolded against a supportive backdrop for biotechnology and healthcare names, with sector peers trading broadly firmer during the session. The move also appeared amplified by above-average trading activity, as investors repositioned around the earnings report and its clinical readouts. Technically, the stock recovered from a recent pullback toward its mid-$28 range and reclaimed levels near its short-term moving averages, signaling renewed buying interest after several sessions of consolidation.
What Comes Next for IMCR
Looking ahead, the key catalyst is the topline overall survival readout from the TEBE-AM trial, anticipated in the second quarter of 2027, which could define the commercial runway for KIMMTRAK beyond uveal melanoma. Nearer term, investors will monitor additional brenetafusp data expected at a medical conference later this year, progress on the DUET-UVEAL trial, and execution of the autoimmune pipeline. Risks include the company's reliance on a single marketed product, a $120 million sales-related rebate accrual expected in the fourth quarter, and the inherent uncertainty of clinical trial outcomes. The recent earnings-driven move suggests the market is increasingly focused on pipeline optionality rather than near-term profitability.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of automated approaches to explore. If you're interested in data-driven trading ideas, consider exploring the Trending AI Robots page to see which strategies are currently performing well.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IMCR in +4.25% Uptrend, growing for three consecutive days on October 28, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IMCR advanced for three days, in 219 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMCR's RSI Oscillator exited the oversold zone, 19 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMCR as a result. In 58 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for IMCR turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
IMCR moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for IMCR moved below the 200-day moving average on November 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
IMCR broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMCR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.802) is normal, around the industry mean (3.482). IMCR has a moderately low P/E Ratio (-86.083) as compared to the industry average of (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.791) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. IMCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement